POTS Disease and COVID: The Link, Symptoms, and Management

SARS-CoV-2 infection has become one of the most common triggers of postural orthostatic tachycardia syndrome, a condition in which the heart races abnormally when you stand up. Before the pandemic, POTS was diagnosed at a rate of roughly 1.4 per million people; afterward, that rate climbed to nearly 23 per million, a more than fifteenfold increase.¹ The connection is strong enough that a recent review estimates 30 to 40 percent of POTS cases now begin within three months of an infection like COVID-19.² Understanding this link matters because post-COVID POTS can be debilitating, and getting the right diagnosis is the first step toward a management plan that actually helps.

How Common Is POTS After COVID-19

The numbers depend on whom you study and how carefully you look. Among people attending specialized long-COVID clinics with significant ongoing symptoms, about 31 percent meet the formal diagnostic criteria for POTS.³ That figure climbs even higher when you include people who show some signs of abnormal heart-rate response without crossing every diagnostic threshold. In one cardiology study of post-acute COVID patients, about 30 percent met the specific heart-rate cutoff on a standing test, and nearly three-quarters had at least one measurable cardiovascular autonomic abnormality.⁴

These clinic-based numbers overstate what happens in the general population, since people with severe symptoms are the ones who show up at specialty centers. Broader population-level data paints a less alarming but still striking picture. An analysis of over 12,000 patients with documented SARS-CoV-2 infection found hundreds of new POTS-associated diagnoses in the months after infection, with those diagnosed tending to be slightly older and more commonly female.⁵ The pandemic did not create POTS from scratch, but it gave the condition a much larger patient population almost overnight.

What POTS Actually Feels Like

The hallmark symptom is a racing heart when you stand up from sitting or lying down. But most people with POTS will tell you the heart rate is the least of their problems. The real burden is everything that comes with the faulty circulatory response: dizziness, lightheadedness, brain fog, crushing fatigue, and a feeling that your body simply cannot tolerate being upright for long. Some people faint; many more feel like they are about to.

Post-COVID POTS tends to arrive alongside a constellation of other issues. In long-COVID cohorts, pain is reported by the vast majority of patients, along with neurological symptoms, sleep disruption, and skin changes. More than half screen positive for the kind of fatigue and post-exertional malaise that characterizes chronic fatigue syndrome.⁶ This overlap matters because it means your doctor should not stop at a POTS label. If standing makes your heart race and you also have widespread pain, terrible sleep, and cognitive fog, the autonomic dysfunction is part of a bigger picture.

One symptom that catches many patients off guard is exercise intolerance. People who were previously fit describe becoming unable to walk a block without feeling wiped out. The American Heart Association has noted that nearly all patients with long COVID report severe fatigue, shortness of breath, and reductions in exercise tolerance.⁷ This is not just being “out of shape.” It reflects a real physiological disruption in how the body manages blood flow during activity.

Why COVID Triggers Autonomic Dysfunction

Researchers have identified several mechanisms, and the honest answer is that more than one probably operates at the same time. No single explanation accounts for every patient’s experience, which is one reason treatment needs to be personalized.

One prominent theory involves autoantibodies. After fighting off the virus, some people’s immune systems start producing antibodies that mistakenly target receptors involved in blood vessel tone and heart rate regulation. A study of long-COVID patients found that autoantibodies against multiple receptor types were linked to changes in heart rate variability and blood pressure responses during stress tests.⁸ In plain terms, your immune system starts interfering with the signals your nervous system uses to control your circulation.

A second pathway involves damage to small nerve fibers. These are the tiny nerves in your skin and organs that help regulate things like sweating and blood vessel constriction. A case-control study found that long-COVID patients diagnosed with small fiber neuropathy on skin biopsy overwhelmingly reported the kind of post-exertional malaise typical of chronic fatigue syndrome, and exercise testing confirmed abnormal blood flow regulation consistent with autonomic dysfunction.⁹ When these nerve fibers are damaged, the body loses its ability to properly squeeze blood vessels when you stand, and blood pools in your legs instead of returning to your heart and brain.

A third mechanism centers on abnormal blood clotting. COVID-19 is known to cause inflammation of the blood vessel lining and hyperactivation of platelets, leading to tiny, abnormally structured clots called fibrinaloid microclots.¹⁰ These microclots can obstruct the smallest blood vessels, reducing oxygen delivery to tissues. One line of research argues that this tissue-level oxygen deprivation may be a chief intermediary cause of POTS, with the rapid heart rate being the body’s attempt to compensate for the poor oxygen supply.¹¹

Finally, some post-COVID POTS patients show a hyperadrenergic pattern, meaning their body floods with the stress hormone norepinephrine when they stand. A deep-phenotyping study found that about 38 percent of long-COVID POTS participants had elevated upright norepinephrine levels consistent with this hyperadrenergic response.¹² These patients tend to have surges in blood pressure along with the heart rate increase, plus flushing, tremor, and anxiety that can be mistaken for a panic attack.

Getting Diagnosed

The formal criteria require a heart rate increase of 30 beats per minute or more in adults (40 or more in adolescents) within ten minutes of standing or being tilted upright, along with a history of symptoms related to being upright, and without a significant drop in blood pressure.¹³ The symptoms need to have been present for at least three months to distinguish POTS from the temporary autonomic disruption that many illnesses can cause.

In practice, testing is less standardized than those crisp criteria suggest. A tilt-table test, where you lie on a motorized table that tilts you upright, is the traditional gold standard, but it has a surprisingly high rate of false positives. Research comparing passive tilt to active standing found that using the standard 30-beat-per-minute cutoff on a 30-minute tilt test would have falsely diagnosed 80 percent of healthy control subjects, compared to 47 percent with an active standing test.¹⁴ The study suggested that the tilt test may need a higher heart-rate threshold (around 38 beats per minute at 10 minutes, or 47 at 30 minutes) to be accurate. A simple active-standing test in a doctor’s office, using the standard 30-beat-per-minute threshold, was actually more specific.

This is worth knowing because many people go years without a diagnosis. The average time from symptom onset to POTS diagnosis has historically been measured in years, though awareness has improved since the pandemic. If your doctor is dismissive but your heart rate reliably jumps 30-plus beats per minute just from standing, you have objective data to push for further evaluation. A basic heart-rate monitor or even a smartwatch can give you a starting point.

Medications That Help

There is no single drug that works for everyone, and treatment usually involves trying different options and combining them. The choice often depends on which subtype of POTS a person has, which is why figuring out the underlying mechanism matters.

Ivabradine has become one of the more studied medications for post-COVID POTS specifically. It works by slowing the heart rate without lowering blood pressure, which is a useful distinction because many POTS patients already have low or unstable blood pressure. A meta-analysis found that ivabradine reduced standing heart rate by about 19 beats per minute and supine heart rate by about 10 beats per minute, with symptom improvement reported across classic, pediatric, hyperadrenergic, and post-COVID subgroups.¹⁵ In a single-center study focused on post-COVID POTS, roughly 78 percent of patients reported significant symptom improvement within a week of starting the drug.¹⁶

Beta-blockers like propranolol and bisoprolol are older options that remain widely used. They work best for the hyperadrenergic subtype, where excess sympathetic nervous system activity is driving the rapid heart rate. A randomized trial comparing propranolol, bisoprolol, pyridostigmine (a drug that enhances the parasympathetic “rest and digest” side of the nervous system), and combinations of these found that orthostatic symptom scores dropped significantly over three months in all groups. The improvements were similar regardless of which drug or combination was used.¹⁷ The physical aspects of quality of life improved in every group, and depression scores improved even without antidepressants.

For the neuropathic subtype, where the problem is poor blood vessel constriction rather than overactive adrenaline, agents like midodrine (which squeezes blood vessels) and pyridostigmine are often preferred.¹⁸ Many clinicians combine approaches: a rate-slowing drug with a vasoconstrictor with lifestyle measures. Finding the right combination takes patience, and what works brilliantly for one person may do nothing for another.

Lifestyle Measures and Rehabilitation

Before or alongside medication, most clinicians recommend a package of lifestyle adjustments. The simplest and most effective, according to patient surveys, is increasing fluid and salt intake. In a study of POTS patients, about 58 percent found fluid and salt loading helpful for managing symptoms, a higher rate of perceived effectiveness than medications (43 percent) or exercise (21 percent).¹⁹ The logic is straightforward: more fluid and salt means more blood volume, which makes it harder for blood to pool in the legs when you stand.

Compression garments are frequently recommended, but the evidence for them is mixed. In that same survey, only about 9 percent of patients found compression helpful for symptom mitigation.¹⁹ One newer study has investigated abdominal-only compression garments, which target the large venous reservoir in the abdomen rather than the legs, and found they reduced orthostatic tachycardia and improved symptoms.²⁰ Waist-high compression may simply be more practical and more physiologically targeted than knee-high stockings.

Exercise is tricky. There has been genuine concern about whether exercise training is safe for long-COVID patients, particularly those with post-exertional malaise. The American Heart Association has acknowledged this concern but concluded that exercise appropriately tailored to the individual, particularly for those whose main issue is cardiovascular deconditioning, can be effective at improving symptoms.⁷ The key words there are “appropriately tailored.” Many POTS protocols start with recumbent exercises (rowing, swimming, recumbent cycling) to avoid the upright posture that triggers symptoms, and progress very slowly. Pushing too hard, too fast, especially if you also have post-exertional malaise, can set you back significantly.

Immunotherapy for Refractory Cases

For patients whose POTS is severe and does not respond to standard medications or lifestyle changes, some clinicians have turned to immune-targeted treatments. The rationale follows from the autoimmune mechanisms described earlier: if rogue antibodies are interfering with your nervous system’s ability to regulate circulation, suppressing or removing those antibodies should help.

Case reports and small case series have shown benefit from intravenous immunoglobulin (IVIG), plasmapheresis (filtering the blood to remove autoantibodies), corticosteroids, and the immune-suppressing drug rituximab in patients with severe POTS refractory to standard therapies.²¹ Early case reports in post-COVID patients showed IVIG could improve both orthostatic symptoms and small fiber neuropathy. The evidence here is still at the case-report level, not from randomized trials, so these treatments remain reserved for the most treatment-resistant patients. They are also expensive and carry their own risks. But for someone who has tried everything else and remains severely disabled, they represent a real option worth discussing with a specialist.

Vagus Nerve Stimulation as an Emerging Tool

One of the more intriguing new approaches involves stimulating the vagus nerve through the skin of the ear, a technique called transcutaneous vagus nerve stimulation (tVNS) or low-level tragus stimulation. The vagus nerve is the main parasympathetic “brake” on the heart, and the idea is that stimulating it can help rebalance a nervous system that has become stuck in overdrive.

A study of post-COVID POTS patients found that a month of tragus stimulation significantly reduced the heart-rate increase from lying to standing, lowered average and maximum heart rates, and improved markers of nervous system balance. These effects persisted through a year of follow-up.²² A separate proof-of-concept trial specifically in hyperadrenergic POTS found that two weeks of tVNS enhanced the vagal (calming) component of heart-rate regulation, reduced sympathetic activity, and improved orthostatic symptoms, with some benefits lasting beyond the stimulation period.²³

These are small studies, and no one should treat them as definitive. But they are notable because tVNS is noninvasive, low-risk, and relatively inexpensive compared to medications or immunotherapy. Consumer-grade ear-clip vagus nerve stimulators already exist. If larger trials confirm these results, tVNS could become a useful add-on therapy, especially for the hyperadrenergic subtype where sympathetic overdrive is the main problem.

The Long View on Recovery

One of the hardest questions for anyone newly diagnosed with post-COVID POTS is whether it will get better. The honest answer is that it depends, and the data so far is not especially reassuring for the most severely affected patients. A two-year prospective study tracking people with post-COVID syndrome found that the condition can develop into a chronic syndrome with long-lasting symptoms and impairment. Patients who met the strictest criteria for chronic fatigue had particularly low chances of significant improvement over 20 months of follow-up, despite receiving symptomatic treatment.²⁴

That said, POTS itself is not necessarily a lifelong sentence. Many people with POTS from causes other than COVID do improve over months to years, especially with consistent treatment and graded exercise. The post-COVID cohort is still young in follow-up terms, and some patients do recover substantially, particularly those whose main issue is deconditioning rather than autoimmune nerve damage. The challenge is that there is no reliable way yet to predict who will recover quickly and who will not. Younger patients, those with milder initial illness, and those without overlapping chronic fatigue syndrome may have better odds, but these are tendencies rather than rules.

For now, the best strategy is to pursue aggressive, multimodal treatment (combining medications, lifestyle changes, and graded rehabilitation) rather than waiting to see if symptoms resolve on their own. The randomized trial data on beta-blockers and pyridostigmine showed that sustained treatment improved not only orthostatic symptoms but also depression and quality of life over three months, even without antidepressants.¹⁷ Treatment works better the earlier and more consistently it is applied.

Why Post-COVID POTS Gets Missed

Despite the surge in cases, many patients with post-COVID POTS still wait months or years for a diagnosis. Part of the problem is that the symptoms overlap with anxiety, depression, and deconditioning, and clinicians who are not familiar with POTS may default to those explanations. A racing heart, lightheadedness, and brain fog after COVID can look a lot like a panic disorder on paper, especially if the doctor does not check heart rate in different body positions.

Another part of the problem is the testing itself. As noted earlier, a standard tilt-table test can produce false positives in a majority of healthy people if the standard heart-rate threshold is used without adjustment. This cuts both ways: some patients get told they have POTS when they do not, and others with genuine POTS get told their results are “normal” by clinicians who are skeptical of the diagnosis. An active-standing test in the office, done carefully with proper timing and heart-rate monitoring, is often more informative and certainly more accessible than a formal tilt table.

The overlap with other post-COVID conditions adds another layer of confusion. Dysautonomia in general occurs in a small percentage of patients with the post-COVID condition, but POTS is the most common specific autonomic pattern among them.²⁵ Patients may be told they have “long COVID fatigue” or “post-viral syndrome” without anyone checking whether the fatigue has an identifiable, treatable autonomic component. If you are dealing with persistent symptoms after COVID and have not had your heart rate checked lying down and then standing, that is a conversation worth having with your doctor.

1
PubMed Central. Postural orthostatic tachycardia syndrome in post-COVID-19 long-hauler patients is associated with platelet storage pool deficiency
2
JAMA. Postural Orthostatic Tachycardia Syndrome (POTS): A Review
3
PubMed. Prevalence and Clinical Impact of Postural Orthostatic Tachycardia Syndrome in Highly Symptomatic Long COVID
4
PubMed Central / Canadian Journal of Cardiology. Objective Hemodynamic Cardiovascular Autonomic Abnormalities in Post-Acute Sequelae of COVID-19
5
Nature Cardiovascular Research. Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection
6
PubMed Central. Overlapping conditions in Long COVID at a multisite academic center
7
Circulation. Exercise Intolerance and Response to Training in Patients With Postacute Sequelae of SARS-CoV2 (Long COVID): A Scientific Statement From the American Heart Association
8
PubMed. Autonomic dysfunction and vasoregulation in long COVID-19 are linked to anti-GPCR autoantibodies
9
PubMed Central. Case-Control Study of Individuals With Small Fiber Neuropathy After COVID-19
10
PubMed Central. Long COVID: pathophysiological factors and abnormalities of coagulation
11
PubMed Central. Possible Role of Fibrinaloid Microclots in Postural Orthostatic Tachycardia Syndrome (POTS): Focus on Long COVID
12
medRxiv. Long-COVID Postural Tachycardia Syndrome: A deep phenotyping study
13
The American Journal of Medicine. Postural Orthostatic Tachycardia Syndrome (POTS) and Dysautonomia: International Multidisciplinary Expert Consensus
14
PubMed Central. Diagnosing Postural Tachycardia Syndrome: Comparison of Tilt Test versus Standing Hemodynamics
15
PubMed. Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis
16
PubMed Central. Ivabradine effects on COVID-19-associated postural orthostatic tachycardia syndrome: a single center prospective study
17
PubMed Central. Efficacy of Propranolol, Bisoprolol, and Pyridostigmine for Postural Tachycardia Syndrome: a Randomized Clinical Trial
18
Current Problems in Cardiology. Pathophysiology and management of postural orthostatic tachycardia syndrome (POTS): A literature review
19
PubMed Central. Current Landscape of Compression Products for Treatment of Postural Orthostatic Tachycardia Syndrome and Neurogenic Orthostatic Hypotension
20
PubMed Central. Abdominal-only Compression Garments Reduce Orthostatic Tachycardia and Improve Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome
21
PubMed Central. Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction
22
PubMed Central. Tragus Nerve Stimulation Attenuates Postural Orthostatic Tachycardia Syndrome in Post COVID‐19 Infection
23
PubMed Central. Short and long term effects of a two-week transcutaneous vagus nerve stimulation in hyperadrenergic postural orthostatic tachycardia syndrome: a proof-of-concept trial
24
The Lancet Regional Health. Long-term course of post-COVID-19 syndrome and potential prognostic markers: a two-year prospective observational cohort study
25
PubMed Central. Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies